Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor (CAR) is rapidly emerging as a promising new treatment for haematological and non-haematological malignancies. CAR-T-cell therapy can induce rapid and durable clinical responses, but is associated with unique a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Nat Rev Clin Oncol
Päätekijät: Neelapu, Sattva S., Tummala, Sudhakar, Kebriaei, Partow, Wierda, William, Gutierrez, Cristina, Locke, Frederick L., Komanduri, Krishna V., Lin, Yi, Jain, Nitin, Daver, Naval, Westin, Jason, Gulbis, Alison M., Loghin, Monica E., de Groot, John F., Adkins, Sherry, Davis, Suzanne E., Rezvani, Katayoun, Hwu, Patrick, Shpall, Elizabeth J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6733403/
https://ncbi.nlm.nih.gov/pubmed/28925994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2017.148
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia